This grant from the National Institutes of Health aims to support the validation of strong candidate biomarkers and endpoints for pain to aid in the development of non-opioid pain therapeutics. The focus is on advanced analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints using retrospective and/or prospective methods. The goal is to demonstrate reliable correlation of biomarker or endpoint change with variables like clinical outcome and therapeutic response, ensuring specificity to the pain condition or therapeutic. Successful research funded by this grant will advance robust biomarkers for application in clinical trials and clinical practice.
Opportunity ID: 309098
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-18-046 |
| Funding Opportunity Title: | Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Food and Nutrition Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 19, 2018 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Mar 12, 2020 |
| Current Closing Date for Applications: | Mar 12, 2020 |
| Archive Date: | Apr 17, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public housing authorities/Indian housing authorities Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Small businesses For profit organizations other than small businesses State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments County governments Native American tribal governments (Federally recognized) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. Specifically, the focus of this FOA is on advanced analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints using retrospective and/or prospective methods. It is assumed that: 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding Context of Use is in place. Research supported by this FOA will ultimately demonstrate that biomarker or endpoint change is reliably correlated with variables such as clinical outcome, pathophysiologic subsets of pain, therapeutic target engagement or response to a pain therapeutic; in addition, biomarker response will demonstrate specificity to the pain condition or therapeutic as demonstrated at multiple clinical sites. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers, biomarker signatures and endpoints of pain to application in clinical trials (Phase II clinical trials and beyond) and in the spectrum of clinical practice. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-046.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00244970 | Oct 27, 2018 | May 24, 2020 | View |
Package 1
Mandatory forms
309098 RR_SF424_2_0-2.0.pdf
309098 PHS398_CoverPageSupplement_4_0-4.0.pdf
309098 RR_OtherProjectInfo_1_4-1.4.pdf
309098 PerformanceSite_2_0-2.0.pdf
309098 RR_KeyPersonExpanded_2_0-2.0.pdf
309098 RR_Budget_1_4-1.4.pdf
309098 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
309098 RR_SubawardBudget30_1_4-1.4.pdf
309098 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
